Royce & Associates’s West Pharmaceutical WST Stock Holding History

Royce & Associates’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,000	Closed	-$907K	–	976
2022 Q2	$907K	Sell	3,000 -3,000	-50%	-$976K	0.01%	764
2022 Q1	$2.46M	Hold	6,000	–	–	0.02%	684
2021 Q4	$2.81M	Hold	6,000	–	–	0.02%	672
2021 Q3	$2.55M	Hold	6,000	–	–	0.02%	710
2021 Q2	$2.15M	Hold	6,000	–	–	0.01%	751
2021 Q1	$1.69M	Hold	6,000	–	–	0.01%	783
2020 Q4	$1.7M	Sell	6,000 -2,000	-25%	-$561K	0.01%	755
2020 Q3	$2.2M	Hold	8,000	–	–	0.02%	661
2020 Q2	$1.82M	Sell	8,000 -15,000	-65%	-$2.95M	0.02%	684
2020 Q1	$3.5M	Hold	23,000	–	–	0.05%	465
2019 Q4	$3.46M	Sell	23,000 -6,000	-21%	-$874K	0.03%	580
2019 Q3	$4.11M	Hold	29,000	–	–	0.04%	525
2019 Q2	$3.63M	Hold	29,000	–	–	0.03%	571
2019 Q1	$3.2M	Hold	29,000	–	–	0.03%	614
2018 Q4	$2.84M	Buy	29,000 +6,000	+26%	+$651K	0.03%	628
2018 Q3	$2.84M	Hold	23,000	–	–	0.02%	749
2018 Q2	$2.28M	Hold	23,000	–	–	0.02%	805
2018 Q1	$2.03M	Hold	23,000	–	–	0.01%	852
2017 Q4	$2.27M	Hold	23,000	–	–	0.02%	817
2017 Q3	$2.21M	Hold	23,000	–	–	0.01%	806
2017 Q2	$2.17M	Hold	23,000	–	–	0.01%	826
2017 Q1	$1.88M	Hold	23,000	–	–	0.01%	876
2016 Q4	$1.95M	Buy	+23,000	New	+$1.81M	0.01%	832
2013 Q4	–	Sell	-20,800	Closed	-$856K	–	1484
2013 Q3	$856K	Buy	20,800 +6,200	+42%	+$237K	﹤0.01%	1195
2013 Q2	$513K	Buy	+14,600	New	+$480K	﹤0.01%	1232

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's WST Position: Q3 2022 in Review

Royce & Associates sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 3,000 shares — an estimated $907K sold.

Royce & Associates first reported a position in WST in Q2 2013 and held it in 25 quarters. The position peaked at $4.11M in Q3 2019. 637 funds tracked by Wall St. Rank hold WST as of Q3 2022.

Royce & Associates reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Royce & Associates sold 3,000 West Pharmaceutical shares in Q3 2022, an estimated $907K.
Royce & Associates first reported a position in West Pharmaceutical in Q2 2013 and held it in 25 quarters.
Royce & Associates's West Pharmaceutical position peaked at $4.11M in Q3 2019.
637 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Royce & Associates's 13F filing for Q3 2022, filed 3 Nov 2022.